In a filing, Ionis Pharmaceuticals Inc revealed its EVP CLO & General Counsel O’NEIL PATRICK R. unloaded Company’s shares for reported $0.11 million on Sep 12 ’25. In the deal valued at $64.58 per share,1,700 shares were sold. As a result of this transaction, O’NEIL PATRICK R. now holds 57,130 shares worth roughly $3.66 million.
Then, Baroldi Joseph sold 11,950 shares, generating $742,838 in total proceeds. Upon selling the shares at $62.16, the EVP, Chief Business Officer now owns 31,926 shares.
Before that, O’NEIL PATRICK R. sold 21,000 shares. Ionis Pharmaceuticals Inc shares valued at $1,355,661 were divested by the EVP CLO & General Counsel at a price of $64.56 per share. As a result of the transaction, O’NEIL PATRICK R. now holds 57,130 shares, worth roughly $3.66 million.
Goldman upgraded its Ionis Pharmaceuticals Inc [IONS] rating to a Neutral from a a Sell in a research note published recently. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who increased its forecast for the stock in early September from “a Market perform” to “an Outperform”. Morgan Stanley also remained covering IONS and has increased its forecast on July 31, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating. Barclays revised its rating on July 01, 2025. It rated IONS as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of IONS
On Friday, Ionis Pharmaceuticals Inc [NASDAQ:IONS] saw its stock jump 1.78% to $64.09. Over the last five days, the stock has gained 5.05%. Ionis Pharmaceuticals Inc shares have risen nearly 56.32% since the year began. Nevertheless, the stocks have risen 83.32% over the past one year. While a 52-week high of $64.71 was reached on 09/10/25, a 52-week low of $23.95 was recorded on 04/09/25.
Levels Of Support And Resistance For IONS Stock
The 24-hour chart illustrates a support level at 63.26, which if violated will result in even more drops to 62.44. On the upside, there is a resistance level at 64.70. A further resistance level may holdings at 65.32.
How much short interest is there in Ionis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Ionis Pharmaceuticals Inc stocks on 2025-09-15, growing by 1.19 million shares to a total of 11.97 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 10.79 million shares. There was a rise of 9.92%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 07, 2025 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
